Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Retatrutide is still awaiting FDA approval, but early data is certainly encouraging
As of June 2026 it is not Category 1 and is not eligible for 503A compounding
The New England Journal of Medicine, 384 (11), 989-1002
Diabetic Retinopathy - Complications of diabetic retinopathy in Semaglutide clinical trials have been seen only in patients with type 2 diabetes mellitus and those with a body mass index corresponding to being overweight
The established safety profile and predictable pharmacology reduce development risks while enabling confident investment in manufacturing infrastructure and market development initiatives
US$ 25.19
US$ 27.58
US$ 22.87
US$ 21.44
US$ 24.83
US$ 21.14
US$ 24.92
US$ 22.57
US$ 20.23
US$ 22.77
US$ 25.81
US$ 26.99
US$ 22.23
